Calcium-binding proteins are altered in the cerebellum in schizophrenia
dc.contributor.author | Vidal Domènech, Francisco | |
dc.contributor.author | Riquelme, Gemma | |
dc.contributor.author | Pinacho, Raquel | |
dc.contributor.author | Rodríguez Mias, Ricard | |
dc.contributor.author | Vera, América | |
dc.contributor.author | Monje, Alfonso | |
dc.contributor.author | Ferrer, Isidre | |
dc.contributor.author | Callado Hernando, Luis Felipe | |
dc.contributor.author | Meana Martínez, José Javier | |
dc.contributor.author | Villén, Judit | |
dc.contributor.author | Ramos, Belén | |
dc.date.accessioned | 2020-12-16T13:14:01Z | |
dc.date.available | 2020-12-16T13:14:01Z | |
dc.date.issued | 2020-07-08 | |
dc.identifier.citation | Plos One 15(7) : (2020) // Article ID e0230400 | es_ES |
dc.identifier.issn | 1932-6203 | |
dc.identifier.uri | http://hdl.handle.net/10810/49115 | |
dc.description.abstract | Alterations in the cortico-cerebellar-thalamic-cortical circuit might underlie the diversity of symptoms in schizophrenia. However, molecular changes in cerebellar neuronal circuits, part of this network, have not yet been fully determined. Using LC-MS/MS, we screened altered candidates in pooled grey matter of cerebellum from schizophrenia subjects who committed suicide (n = 4) and healthy individuals (n = 4). Further validation by immunoblotting of three selected candidates was performed in two cohorts comprising schizophrenia (n = 20), non-schizophrenia suicide (n = 6) and healthy controls (n = 21). We found 99 significantly altered proteins, 31 of them previously reported in other brain areas by proteomic studies. Transport function was the most enriched category, while cell communication was the most prevalent function. For validation, we selected the vacuolar proton pump subunit 1 (VPP1), from transport, and two EF-hand calcium-binding proteins, calmodulin and parvalbumin, from cell communication. All candidates showed significant changes in schizophrenia (n = 7) compared to controls (n = 7). VPP1 was altered in the non-schizophrenia suicide group and increased levels of parvalbumin were linked to antipsychotics. Further validation in an independent cohort of non-suicidal chronic schizophrenia subjects (n = 13) and non-psychiatric controls (n = 14) showed that parvalbumin was increased, while calmodulin was decreased in schizophrenia. Our findings provide evidence of calcium-binding protein dysregulation in the cerebellum in schizophrenia, suggesting an impact on normal calcium-dependent synaptic functioning of cerebellar circuits. Our study also links VPP1 to suicide behaviours, suggesting a possible impairment in vesicle neurotransmitter refilling and release in these phenotypes. | es_ES |
dc.description.sponsorship | Cerrar texto de financiación This work was supported by a Miguel Servet grant (MS16/00153-CP16/00153) to BR financed and integrated into the National R + D + I and funded by the Instituto de Salud Carlos III (Spanish Ministry of Health) - General Branch Evaluation and Promotion of Health Research and the European Regional Development Fund (ERDF), the Basque Government (IT1211/19) and SAF 2017-88126-R to J.J.M. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Public Library Science | es_ES |
dc.relation | info:eu-repo/grantAgreement/MINECO/SAF 2017-88126-R | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.subject | serotonin 5-HT2A receptors | es_ES |
dc.subject | postmortem brain | es_ES |
dc.subject | subunit A1 | es_ES |
dc.subject | H+ -ATPase | es_ES |
dc.subject | parvalbumin | es_ES |
dc.subject | expression | es_ES |
dc.subject | calmodulin | es_ES |
dc.subject | suicide | es_ES |
dc.subject | calbindin | es_ES |
dc.subject | neurons | es_ES |
dc.title | Calcium-binding proteins are altered in the cerebellum in schizophrenia | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.rights.holder | 2020 Vidal-Domènech et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. | es_ES |
dc.rights.holder | Atribución 3.0 España | * |
dc.relation.publisherversion | https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0230400 | es_ES |
dc.identifier.doi | 10.1371/journal.pone.0230400 | |
dc.departamentoes | Farmacología | es_ES |
dc.departamentoeu | Farmakologia | es_ES |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's license is described as 2020 Vidal-Domènech et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.